Announcements

May 3, 2022 – Saol Therapeutics Announces First Patient Enrolled in Phase 2 RAISE Spasticity Trial Evaluating the Safety Profile of SL-1002 for Limb Spasticity

April 26, 2022 – Saol Therapeutics and InformedDNA Partner to Offer Genetic Counseling to Patients with Rare Mitochondrial Disease

March 1, 2022 – Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease

January 5, 2022 – Saol Therapeutics Announces the Divesture of its Baclofen Franchise to Amneal Pharmaceuticals

December 6, 2021 – Saol Therapeutics Announces FDA Approval of LYVISPAH^TM (baclofen) Oral Granules and the Divesture of its Plasma-derived Hyperimmune Portfolio

January 11, 2019 – Saol Therapeutics Announces that CDC Website has Been Updated to Reflect Wide Availability of VARIZIG® (Varicella Zoster Immune Globulin [Human])

August 16, 2018 – Spasticity-related pain reduction and quality of life improvements seen in patients with post-stroke severe spasticity

January 11,2018 – New level 1 evidence for post-stroke severe spasticity

September 1, 2017 – Saol Therapeutics acquires three hyperimmune products from Aptevo Therapeutics

June 30, 2017 – Saol Therapeutics signs co-promotion agreement with Ipsen Biopharmaceuticals for Dysport^® (abobotulinumtoxinA)

January 15, 2016 – Saol Therapeutics acquires Lioresal^® Intrathecal (baclofen injection)

For full prescribing information of Lioresal^® Intrathecal (baclofen injection), including BOXED WARNING, please click here.